Skip to main content
SpringerLink
Log in

Chronic Obstructive Pulmonary Disease in a Managed-Care Setting

  • Original Research Article
  • Published:
Disease Management and Health Outcomes

Abstract

Objective: To identify patterns of care and associated costs for typical patients with chronic obstructive pulmonary disease (COPD) in a US managed-care setting.

Design: Retrospective analysis of administrative data from a proprietary managedcare research database.

Patients: 6371 patients with COPD.

Methods: A ‘core’ population of enrollees was identified who were continuously eligible for healthcare services (including prescription medications) for at least 12 months and who actively utilized services. From this core population, patients with two or more claims listing International Classification of Diseases, nineth edition, Clinical Modification diagnosis codes for COPD were selected as the COPD study population. The core and COPD study databases were then analyzed to quantify healthcare utilization and charges over the period from October 1995 through September 1996.

Results: Approximately one-half of patients with COPD were in the 45- to 64-year age group. The average total healthcare charge for patients with COPD was $US1109 per month (1995/1996 values), compared with $US179 per month for the average patient with healthcare claims. Although only 19% of patients with COPD were hospitalized for COPD, 58% of COPD-attributed healthcare charges were for hospitalizations. Physician visits and tests accounted for another 23% of COPD-attributed healthcare charges, and medications for 9%. Over 25% of patients with COPD had an emergency room visit, compared with 10% of all patients with claims. 40% of patients with COPD received at least one prescription for a respiratory medication during the year. 15% received anticholinergic bronchodilators, 30% received β2-agonist inhalers, 13% received xanthine bron-chodilators, and 14% received inhaled corticosteroids. Patients with COPD had over twice as many medical conditions for which they sought healthcare compared with the average patient with claims.

Conclusions: Although COPD has been viewed as a disease of the elderly, it also significantly affects the quality of life of the ‘not so elderly’, and represents a significant cost exposure to commercial health plans in the US. Despite the availability of acceptable clinical guidelines, there are many opportunities to optimize healthcare utilization and the standard of care for patients with COPD, including ensuring that patients receive those medications considered to be first-line treatment for COPD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Table I
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Institutes of Medicine. Crossing the quality chasm: a new health system for the 21st Century, Washington, DC: National Academy Press, 2001 Mar

    Google Scholar 

  2. Hoffman C, Rice DP, Sung H-Y. Persons with chronic conditions. Their prevalence and costs. JAMA 1996; 276(18): 1473–9

    Article  PubMed  CAS  Google Scholar 

  3. The Robert Wood Johnson Foundation. Chronic Care in America: a 21st century challenge. Princeton (NJ): The Robert Wood Johnson Foundation, 1996 [online] Available from: URL: http://www.rwjf.org/library/chrcare/ [Accessed 2000 Sep]

  4. Wagner EH, Austin BT, Von Korf M. Organizing care for patients with chronic illnesses. Millbank Q 1996; 74(4): 511–42

    Article  CAS  Google Scholar 

  5. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77–120

    Google Scholar 

  6. Petty TL, Winmann GG. Building a national strategy for the prevention and management of and research in chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute Workshop summary. JAMA 1997; 277: 246–53

    Article  PubMed  CAS  Google Scholar 

  7. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127: 1072–9

    PubMed  CAS  Google Scholar 

  8. National Heart, Lung, and Blood Institute. Morbidity and mortality: 1998 chartbook on cardiovascular, lung, and blood diseases. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1998 Oct

  9. Benson V, Marano MA. Current estimates from the National Health Interview Survey 1995. National Center for Health Statistics, Vital Health Statistics 1998; 10(199): 98–1527

    Google Scholar 

  10. National Center for Health Statistics. Advanced report of final mortality statistics, 1973-1994

  11. Farer LS, Schieffelbein CW. Position paper on respiratory disease. In: Closing the gap. Atlanta (GA): The Carter Center of Emory University, Health Policy Project, 1984 Nov

    Google Scholar 

  12. Mak V. Chronic obstructive pulmonary disease (COPD): the UK perspective. Chest medicine on-line [online]. Available from: URL: http://www.222.u_net.com/priory/cmol/copd.html

  13. National Lung Health Education Program Executive Committee. Strategies in preserving lung health and preventing COPD and associated disease: magnitude of the problem and socioeconomic differences. Chest 1998; 113 Suppl 2: 129S

    Google Scholar 

  14. Edelman NH, Kaplan RM, Buist AS, et al. Chronic obstructive pulmonary disease. Task Force on Research and Education for the Prevention and Control of Respiratory Diseases. Chest 1992; 102 Suppl. 3: 243–56

    Google Scholar 

  15. Collins JH. Prevalence of selected chronic conditions: United States 1990–1992. National Center for Health Statistics. Vital Health Stat 1997: 10 (194)

    Google Scholar 

  16. National Center for Health Statistics. Current Estimates from the National Health Interview Survey, United States Selected Years 1971-1994

  17. Rennard SI. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest 1998; 113: 235S–41S

    Article  PubMed  CAS  Google Scholar 

  18. British Thoracic Society. Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997: 52 Suppl. 5

  19. Chen Y, Horne SL, Dosman JA. Increased susceptibility to lung dysfunction in female smokers. Am Rev Respir Dis 1991; 143: 1224–30

    PubMed  CAS  Google Scholar 

  20. Anthionisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bron-chodilator on the rate of decline in FEV1: The lung health study. JAMA 1994; 272: 1497–505

    Article  Google Scholar 

  21. Vilkman S, Keistinen T, Tuuponen T, et al. Survival and cause of death among elderly chronic obstructive pulmonary disease after first admission to hospital. Respiration 1997; 64: 281–4

    Article  PubMed  CAS  Google Scholar 

  22. Rennard SI, Serby CW, Ghafouri M, et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials. Chest 1996; 110: 62–70

    Article  PubMed  CAS  Google Scholar 

  23. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635–41

    Article  PubMed  CAS  Google Scholar 

  24. Imhof E, Elasser S, Karrer W, et al. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive pulmonary lung disease. Respiration 1993; 60: 84–8

    Article  PubMed  CAS  Google Scholar 

  25. Petty TL. The combination of ipratropium and albuterol is more effective than either agent alone. Chest 1995; 107: 183S–6S

    Article  PubMed  CAS  Google Scholar 

  26. Wessling G, Mosert R, Wouters EFM. A comparison of the effects of anticholinergic and [Unsupported Character]2-agonist and combination therapy on respiratory impedance in COPD. Chest 1992: 73

  27. Reisner C, Ferguson GT, Memjoge S, et al. Superiority of a combination metered-dose inhaler containing albuterol and ipratropium over albuterol and ipratropium alone for reversibility testing in chronic obstructive pulmonary disease (COPD). Chest 1997; 112(3S): 82

    Google Scholar 

  28. Zimet I. Pharmacologic therapy of obstructive airway disease. Clin Chest Med 1990; 11: 461–86

    Google Scholar 

  29. Chanez P, Vignola AM, Os’Shaughnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155: 1529–34

    PubMed  CAS  Google Scholar 

  30. Boehringer Ingleheim Pharmaceuticals, Inc. The significance of COPD in managed care. An opportunity to improve outcomes. Ridgefield (CT): Boehringer Ingleheim Pharmaceuticals, Inc., 1999

    Google Scholar 

Download references

Acknowledgements

The author acknowledges that this study was funded by Boehringer Ingelheim Pharmaceuticals, Inc., and their permission to present results from this study is appreciated.

Author information

Authors and Affiliations

  1. Clinical & Scientific Affairs, Boehringer Ingleheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut, CT 06877, USA

    Steven Kesten (Therapeutic Program Director)

Authors
  1. Steven Kesten
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kesten, S. Chronic Obstructive Pulmonary Disease in a Managed-Care Setting. Dis-Manage-Health-Outcomes 9, 589–599 (2001). https://doi.org/10.2165/00115677-200109100-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200109100-00007

Keywords

Search

Navigation